Clinical utility of asthma biomarkers: from bench to bedside

Asthma is a chronic disease characterized by airway inflammation, bronchial hyperresponsiveness, and recurrent episodes of reversible airway obstruction. The disease is very heterogeneous in onset, course, and response to treatment, and seems to encompass a broad collection of heterogeneous disease subtypes with different underlying pathophysiological mechanisms. There is a strong need for easily interpreted clinical biomarkers to assess the nature and severity of the disease. Currently available biomarkers for clinical practice – for example markers in bronchial lavage, bronchial biopsies, sputum, or fraction of exhaled nitric oxide (FeNO) – are limited due to invasiveness or lack of specificity. The assessment of markers in peripheral blood might be a good alternative to study airway inflammation more specifically, compared to FeNO, and in a less invasive manner, compared to bronchoalveolar lavage, biopsies, or sputum induction. In addition, promising novel biomarkers are discovered in the field of breath metabolomics (eg, volatile organic compounds) and (pharmaco)genomics. Biomarker research in asthma is increasingly shifting from the assessment of the value of single biomarkers to multidimensional approaches in which the clinical value of a combination of various markers is studied. This could eventually lead to the development of a clinically applicable algorithm composed of various markers and clinical features to phenotype asthma and improve diagnosis and asthma management.

[1]  H. Boushey,et al.  Analysis of cellular and biochemical constituents of induced sputum after allergen challenge: a method for studying allergic airway inflammation. , 1994, The Journal of allergy and clinical immunology.

[2]  Colin N A Palmer,et al.  Tailored second-line therapy in asthmatic children with the Arg(16) genotype. , 2013, Clinical science.

[3]  C. Palmer,et al.  FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid‐treated asthmatic children , 2011, Allergy.

[4]  K. Chung,et al.  Inflammatory biomarkers in airways of patients with severe asthma compared with non‐severe asthma , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[5]  Peter J Sterk,et al.  An electronic nose in the discrimination of patients with asthma and controls. , 2007, The Journal of allergy and clinical immunology.

[6]  N. Siafakas,et al.  The relationships among hydrogen peroxide in expired breath condensate, airway inflammation, and asthma severity. , 2002, Chest.

[7]  D. Fabian,et al.  The global burden of asthma: executive summary of the GINA Dissemination Committee Report , 2004, Allergy.

[8]  J. Emparanza,et al.  Association among lung function, exhaled nitric oxide, and the CAN questionnaire to assess asthma control in children , 2010, Pediatric pulmonology.

[9]  G. Passalacqua,et al.  Correlation among FEV, nitric oxide and asthma control test in newly diagnosed asthma. , 2007, Allergy.

[10]  J. Priest,et al.  Exhaled nitric oxide levels correlate with measures of disease control in asthma. , 2000, The Journal of allergy and clinical immunology.

[11]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[12]  P. Montuschi.  Exhaled breath condensate: 8-isoprostane and eicosanoids , 2010 .

[13]  Y. Hayashi,et al.  Serum Eosinophil Cationic Protein and 27 Cytokines/Chemokines in Acute Exacerbation of Childhood Asthma , 2010, International Archives of Allergy and Immunology.

[14]  M. Holtzman.  Asthma as a chronic disease of the innate and adaptive immune systems responding to viruses and allergens. , 2012, The Journal of clinical investigation.

[15]  W. Busse,et al.  Eosinophil beta 1 integrin activation state correlates with asthma activity in a blind study of inhaled corticosteroid withdrawal. , 2006, The Journal of allergy and clinical immunology.

[16]  W. Busse,et al.  Up-Regulation and Activation of Eosinophil Integrins in Blood and Airway after Segmental Lung Antigen Challenge1 , 2008, The Journal of Immunology.

[17]  I. Pavord,et al.  TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. , 2002, The Journal of allergy and clinical immunology.

[18]  S. Weiss,et al.  TBX21: A functional variant predicts improvement in asthma with the use of inhaled corticosteroids , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Platts-Mills.  The role of immunoglobulin E in allergy and asthma. , 2001, American journal of respiratory and critical care medicine.

[20]  Zhang Dan,et al.  Increased heat shock protein 70 levels in induced sputum and plasma correlate with severity of asthma patients , 2011, Cell Stress and Chaperones.

[21]  P. J. Barnes,et al.  Increased nitric oxide in exhaled air of asthmatic patients , 1994, The Lancet.

[22]  I. Horváth,et al.  Adenosine triphosphate concentration of exhaled breath condensate in asthma. , 2010, Chest.

[23]  N. Wilson,et al.  Does sputum eosinophilia predict the response to systemic corticosteroids in children with difficult asthma? , 2007, Pediatric pulmonology.

[24]  M. Busslinger,et al.  Transcription factor YY1 is essential for regulation of the Th2 cytokine locus and for Th2 cell differentiation , 2012, Proceedings of the National Academy of Sciences.

[25]  R. Shi,et al.  Discrepancy between clinical asthma control assessment tools and fractional exhaled nitric oxide. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[26]  Nicholas Schork,et al.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment , 1999, Nature Genetics.

[27]  Prescott G Woodruff,et al.  Human asthma phenotypes: from the clinic, to cytokines, and back again , 2011, Immunological reviews.

[28]  A. Armentia,et al.  ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. , 2008, Respiratory medicine.

[29]  Guancong Deng,et al.  A Common Promoter Variant of TBX21 is Associated with Allele Specific Binding to Yin‐Yang 1 and Reduced Gene Expression , 2011, Scandinavian journal of immunology.

[30]  J. Xu,et al.  FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. , 2007, The Journal of allergy and clinical immunology.

[31]  I. Sayers,et al.  Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast , 2000, Thorax.

[32]  F H Krouwels,et al.  Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD , 2011, European Respiratory Journal.

[33]  J. Lammers,et al.  Gradual increase in priming of human eosinophils during extravasation from peripheral blood to the airways in response to allergen challenge. , 2005, The Journal of allergy and clinical immunology.

[34]  L. Koenderman,et al.  Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease , 2009, Clinical and experimental immunology.

[35]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[36]  D. Postma,et al.  The relationship of skin test positivity, high serum total IgE levels, and peripheral blood eosinophilia to symptomatic and asymptomatic airway hyperresponsiveness. , 1999, American journal of respiratory and critical care medicine.

[37]  A. Bush,et al.  Safety and ethics of bronchoscopy and endobronchial biopsy in difficult asthma , 2001, Archives of disease in childhood.

[38]  N. Rabinovitch.  Urinary leukotriene E4 as a biomarker of exposure, susceptibility and risk in asthma. , 2012, Immunology and allergy clinics of North America.

[39]  P. Paggiaro,et al.  Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. , 2006, Chest.

[40]  Tonya S. King,et al.  The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. , 2007, Journal of Allergy and Clinical Immunology.

[41]  C. Lemière,et al.  Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. , 2006, The Journal of allergy and clinical immunology.

[42]  L. Donnelly.  Exhaled breath condensate: nitric oxide- related compounds , 2010 .

[43]  Alphus D. Wilson,et al.  Advances in Electronic-Nose Technologies Developed for Biomedical Applications , 2011, Sensors.

[44]  J. Lammers,et al.  A unique protein profile of peripheral neutrophils from COPD patients does not reflect cytokine-induced protein profiles of neutrophils in vitro , 2011, BMC pulmonary medicine.

[45]  Yusuke Nakamura,et al.  Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. , 2011, The New England journal of medicine.

[46]  L. Koenderman,et al.  Biomarkers of therapy responsiveness in asthma: pitfalls and promises , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[47]  Q. Jöbsis,et al.  Increased cytokines, chemokines and soluble adhesion molecules in exhaled breath condensate of asthmatic children , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[48]  D. Yates,et al.  Role of exhaled nitric oxide in asthma , 2001, Immunology and cell biology.

[49]  L. Donnelly,et al.  Human Airway Inflammation , 2001 .

[50]  I. Adcock,et al.  Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. , 2001, American journal of respiratory and critical care medicine.

[51]  N. Wilson,et al.  Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. , 2005, American journal of respiratory and critical care medicine.

[52]  Leo Koenderman,et al.  A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. , 2012, The Journal of clinical investigation.

[53]  A. Chang,et al.  Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. , 2007, The Cochrane database of systematic reviews.

[54]  Ingo Ruczinski,et al.  Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. , 2009, American journal of human genetics.

[55]  C. Sorkness,et al.  Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. , 2009, The Journal of allergy and clinical immunology.

[56]  S. Mosesova,et al.  Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. , 2011, The Journal of allergy and clinical immunology.

[57]  E. R. Sutherland,et al.  Effect of β2-adrenergic receptor polymorphism on response to longacting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial , 2009, The Lancet.

[58]  S. Wenzel.  Eosinophils in asthma--closing the loop or opening the door? , 2009, The New England journal of medicine.

[59]  S. Stick,et al.  Exhaled nitric oxide and asthma: complex interactions between atopy, airway responsiveness, and symptoms in a community population of children , 2003, Thorax.

[60]  G. Heldt,et al.  Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. , 2005, The Journal of allergy and clinical immunology.

[61]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[62]  Q. Jöbsis,et al.  Childhood asthma: Exhaled markers of airway inflammation, asthma control score, and lung function tests , 2004, Pediatric pulmonology.

[63]  S. Kharitonov,et al.  Exhaled and nasal nitric oxide measurements : recommendations , 1997 .

[64]  J. Lammers,et al.  Expression of activated Fc gamma RII discriminates between multiple granulocyte-priming phenotypes in peripheral blood of allergic asthmatic subjects. , 2007, The Journal of allergy and clinical immunology.

[65]  O. Hankinson,et al.  Hypoxia Inducible Factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis , 2011, Allergy.

[66]  D. Postma,et al.  Genetics of onset of asthma , 2013, Current opinion in allergy and clinical immunology.

[67]  E. Bleecker,et al.  The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. , 2009, The Journal of allergy and clinical immunology.

[68]  R. Hancox,et al.  The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. , 2001, American journal of respiratory and critical care medicine.

[69]  P. Gibson,et al.  Different inflammatory phenotypes in adults and children with acute asthma , 2011, European Respiratory Journal.

[70]  Manuel A. R. Ferreira,et al.  Identification of IL6R and chromosome 11q13.5 as risk loci for asthma , 2011, The Lancet.

[71]  E. Halm,et al.  Detection of immunological biomarkers correlated with asthma control and quality of life measurements in sera from chronic asthmatic patients. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[72]  E. Bleecker,et al.  Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. , 2010, American journal of respiratory and critical care medicine.

[73]  D. Postma,et al.  Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies , 2007, The Lancet.

[74]  R. Effros.  Exhaled breath condensate pH , 2004, European Respiratory Journal.

[75]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[76]  P. J. Barnes,et al.  Exhaled breath condensate: methodological recommendations and unresolved questions , 2005, European Respiratory Journal.

[77]  C. Sorkness,et al.  Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. , 2003, The Journal of allergy and clinical immunology.

[78]  K. Chida,et al.  Relationship of the asthma control test with pulmonary function and exhaled nitric oxide. , 2008, Annals of Allergy, Asthma & Immunology.

[79]  R. Marthan,et al.  Control maintenance can be predicted by exhaled NO monitoring in asthmatic patients. , 2011, Respiratory medicine.

[80]  D. Postma,et al.  Exhaled NO is a poor marker of asthma control in children with a reported use of asthma medication: a pharmacy‐based study , 2012, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[81]  R. Golpe,et al.  Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma , 2009, European Respiratory Journal.

[82]  C. Baena-Cagnani,et al.  Airway remodelling in children: when does it start? , 2007, Current opinion in allergy and clinical immunology.

[83]  Mary Ellen Bates,et al.  Potential Contribution of IL-7 to Allergen-Induced Eosinophilic Airway Inflammation in Asthma1 , 2009, The Journal of Immunology.

[84]  E. Weitzberg,et al.  Increased amount of nitric oxide in exhaled air of asthmatics. , 1993, The European respiratory journal.

[85]  J. D. de Jongste,et al.  Exhaled nitric oxide in childhood asthma: a review , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[86]  E. Wouters,et al.  Exhaled nitric oxide and biomarkers in exhaled breath condensate indicate the presence, severity and control of childhood asthma , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[87]  P. Postmus,et al.  Asthma Genetics and Intermediate Phenotypes: A Review From Twin Studies , 2001, Twin Research.

[88]  P. Barnes,et al.  Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. , 1997, The European respiratory journal.

[89]  L. Shek,et al.  Eosinophil cationic protein : Is it useful in asthma ? , 2007 .

[90]  Wei Guo,et al.  Relationship Between Urinary Cysteinyl Leukotriene E4 Levels and Clinical Response to Antileukotriene Treatment in Patients with Asthma , 2007, Lung.

[91]  A. Chang,et al.  Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. , 2009, The Cochrane database of systematic reviews.

[92]  C. Roussos,et al.  Exhaled nitric oxide and exhaled breath condensate pH in severe refractory asthma. , 2010, Chest.

[93]  A. Michils,et al.  Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients , 2008, European Respiratory Journal.

[94]  P. Barnes,et al.  The cytokine network in asthma and chronic obstructive pulmonary disease. , 2008, The Journal of clinical investigation.

[95]  Niki Fens,et al.  Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. , 2009, American journal of respiratory and critical care medicine.

[96]  N. Borregaard,et al.  Neutrophil granules and secretory vesicles in inflammation. , 2003, Microbes and infection.

[97]  L. Koenderman,et al.  Immunophenotyping of eosinophils recovered from blood and BAL of allergic asthmatics. , 1994, American journal of respiratory and critical care medicine.

[98]  J. Ancochea,et al.  [Bronchoalveolar lavage]. , 1997, Archivos de bronconeumologia.

[99]  Margaret W Leigh,et al.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. , 2011, American journal of respiratory and critical care medicine.

[100]  Florence Demenais,et al.  A large-scale, consortium-based genomewide association study of asthma. , 2010, The New England journal of medicine.

[101]  Zhenyu Liang,et al.  Erratum to: Increased heat shock protein 70 levels in induced sputum and plasma correlate with severity of asthma patients , 2011, Cell Stress and Chaperones.

[102]  H. Kerstjens,et al.  Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[103]  M. Klinnert,et al.  Interleukin-10 and transforming growth factor-β promoter polymorphisms in allergies and asthma , 1998 .

[104]  A. Bush,et al.  Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. , 2012, The Journal of allergy and clinical immunology.

[105]  P. Sterk,et al.  Asthma therapy and airway remodeling. , 2007, The Journal of allergy and clinical immunology.

[106]  Jinho Yu,et al.  Polymorphisms of the PTGDR and LTC4S influence responsiveness to leukotriene receptor antagonists in Korean children with asthma , 2011, Journal of Human Genetics.

[107]  E. Wouters,et al.  Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in children , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[108]  J. Fahy,et al.  Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. , 2009, Proceedings of the American Thoracic Society.

[109]  Ashley Woodcock,et al.  Non-invasive phenotyping using exhaled volatile organic compounds in asthma , 2011, Thorax.

[110]  W. Busse,et al.  Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. , 2010, Respiratory medicine.

[111]  T. Karagiannis,et al.  Biologics: Targets and Therapy , 2013 .

[112]  R. Scott,et al.  Inflammatory subtypes in asthma: Assessment and identification using induced sputum , 2006, Respirology.

[113]  L. Trinquart,et al.  Multicentre trial evaluating alveolar NO fraction as a marker of asthma control and severity , 2010, Allergy.